Clearly one of us has no idea about IMU's intent. And yet you are very persistent with your deranged ramblings.
Its not rocket science, but even then it is probably too complicated for you to understand. They cannot trial two investigational drugs together (onCARlytics and Azercell) if they are both trial drugs at such an early stage in the trials. That would be kind of stupid and a waste of time, because they would not be able to attribute the side effects or efficacy to one particular drug. They are only trialing a combo with Blinatumomab because its already on the market and there is already a mountain of data pertaining to its profile. This will provide them with further evidence that onCARlytics is a viable solution to work in combination with other drugs that required CD19 targeting.
If you cannot see the clear end game then you certainly have blinkers on, and to be honest most people reading your tripe see right through it. I don't even know why I am engaging, I usually wouldn't waste my energy on trolls. Must be having one of those days
IMU Price at posting:
3.6¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)